Key Takeaways PFE may post a Q2 beat as growth in Vyndaqel and Padcev are likely to offset weaker Prevnar and Ibrance sales.LLY's Q2 sales likely to have been aided by strong demand for Mounjaro, Zepbound and other key therapies.GILD's HIV and hepatitis portfolios are likely to have boosted Q2 sales, driven by demand for Biktarvy.The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, with many large drugmakers like Pfizer (PFE) , Eli Lil ...